BioNTech to pay $1.2 billion over vaccine royalties
BioNTech SE ADR closed $18.91 short of its 52-week high ($131.49), which the company achieved on September 17th.
Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
South Korea's parliament impeached acting President Han Duck-soo on Friday, less than two weeks after suspending President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback